<DOC>
	<DOCNO>NCT00981318</DOCNO>
	<brief_summary>This study assess response lopinavir/ritonavir plus maraviroc ( nucleoside medication ) HIV patient fail initial antiviral therapy .</brief_summary>
	<brief_title>Pilot Assessment Lopinavir/Ritonavir Maraviroc</brief_title>
	<detailed_description>As long-term toxicity many nucleoside medication become know , interest increase treatment regimen use medication . This study ass response one `` nucleoside-sparing '' therapy patient show failure initial nucleoside-containing treatment regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV viral load &gt; 1,000 current antiviral medication No resistance study medication Over 18 year age Hepatitis B coinfection Pregnancy Previous therapy either study medication Ongoing substance abuse Significant history physical disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>treatment experience</keyword>
</DOC>